EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.

@article{Phuchareon2015EGFRIE,
  title={EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.},
  author={Janyaporn Phuchareon and Frank Mccormick and David W. Eisele and Osamu Tetsu},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2015},
  volume={112 29},
  pages={E3855-63}
}
Nonsmall cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. About 14% of NSCLCs harbor mutations in epidermal growth factor receptor (EGFR). Despite remarkable progress in treatment with tyrosine kinase inhibitors (TKIs), only 5% of patients achieve tumor reduction >90%. The limited primary responses are attributed partly to drug resistance inherent in the tumor cells before therapy begins. Recent reports showed that activation of receptor tyrosine kinases (RTKs) is an… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

HDAC10 promotes lung cancer proliferation via AKT phosphorylation

Oncotarget • 2016
View 4 Excerpts
Highly Influenced

ETS-targeted therapy: can it substitute for MEK inhibitors?

Clinical and translational medicine • 2017
View 5 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Functional cooperation between Stat-1 and ets-1 to optimize icam-1 gene transcription.

Biochemistry and cell biology = Biochimie et biologie cellulaire • 2009
View 7 Excerpts
Highly Influenced

The clinical development of MEK inhibitors

Nature Reviews Clinical Oncology • 2014
View 1 Excerpt

Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione

R Rosell
Italiana Oncologia Toracica • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…